BLINCYTO ® is the first and only bispecific CD19-directed CD3 T cell engager 1,2 1. BLINCYTO ® (blinatumomab) Prescribing Information, Amgen. 2. Food and Drug Administration.. There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06).. Besponsa (inotuzumab) is an antibody drug conjugate which is comprised of a monoclonal antibody targeting CD22, a cell surface antigen expressed on around 90 percent of B-cell malignancies, linked to a cytotoxic agent.. BLINCYTO ® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy.. Interrupt BLINCYTO until resolved, then restart BLINCYTO at 9 mcg/day. Escalate to 28 mcg/day after 7 days if the toxicity does not recur. Escalate to 28 mcg/day after 7 days if the toxicity does not recur.. Besponsa's black box blunts Blincyto challenge. August 18, 2017. Pfizer (NYSE:PFE) has bagged approval for its antibody-drug conjugate Besponsa, but a black box warning for liver damage could make .